Table 1. FDA-approved combination of immunotherapy with other therapies for various cancers.
| Combination | Drug | Indication | Date of approval | Ref. |
| Anti-PD-1+Anti-CTLA-4 | Nivolumab+Ipilimumab | First-line treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC) | April 17,2018 | [76] |
| Refractory dMMR–MSI-H colorectal cancer (CRC). | July 10,2018 | [77] | ||
| Unresectable malignant pleural mesothelioma | October 2, 2020 | [78] | ||
| Hepatocellular carcinoma (HCC) patients previously treated with Sorafenib | March 10,2020 | [79] | ||
| First-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. | May 15, 2020 | [80] | ||
| Anti-PD-1+Anti-CTLA-4+chemotherapy | Nivolumab+Ipilimumab+platinum | First-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. | May 26, 2020 | [81] |
| Anti-PD1+chemotherapy | Pembrolizumab +Pemetrexed+Platinum | Advanced cervical cancer with disease progression | July 12,2018 | [82] |
| First-line treatment of patients with metastatic, non-squamous non-small cell lung cancer (NSqNSCLC), with no EGFR or ALK genomic tumor aberrations. | August 20, 2018 | [83] | ||
| Pembrolizumab+platinum | Advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. | April 16, 2021 | [84] | |
| Pembrolizumab+Platinum+fluorouracil | Head and neck squamous cell carcinoma (HNSCC) | June 10,2019 | [85] | |
| Anti-PD-L1+chemotherapy | Atezolizumab+paclitaxel protein-bound | Adults with PD-L1-positive, unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) | March 08, 2019 | [86] |
| Atezolizumab+ Bevacizumab+Carboplatin+Paclitaxel |
First-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (Nsq NSCLC) with no EGFR or ALK genomic tumor aberrations. | December 6,2018 | [87] | |
| Anti-PD-L1+Anti-VEGF | Atezolizumab+ Bevacizumab |
Hepatocellular carcinoma (HCC) | May 29,2020 | [88] |
| Anti-PD-1+Anti-VEGFR | Pembrolizumab+Axitinib | Metastatic RCC | April,2019 | [89] |
| Anti-PD-L1+Targeted therapy | Atezolizumab+ Cobimetinib+Vemurafenib |
BRAF V600 mutation-positive unresectable or metastatic melanoma. | July 30, 2020 | [90] |